( - Canadian Biotechnology Company update...)SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference,Health

CALGARY, June 26, 2007 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced positive preclinical data supporting the development of plant-derived recombinant human insulin. The Company presented its findings at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. Specifically, the Company's abstract and poster presentation highlighted its recent accomplishments in the development of a highly-scalable, low-cost source of insulin, including:

    -  Results demonstrating that the Company exceeded its commercial target

       levels of insulin accumulation in safflower, its commercial plant

       system.

    -  Laboratory results demonstrating that safflower-produced insulin is

       physically, structurally and physiologically indistinguishable from

       pharmaceutical-grade human recombinant insulin.

    -  Laboratory results from competitive receptor binding assays

       demonstrating the functional equivalence of the Company's

       safflower-produced insulin to insulin reference standard.

    -  Animal results from insulin tolerance test assays demonstrating the

       pharmacodynamic equivalence of safflower-derived insulin to

       pharmaceutical-grade insulin.

"These results validate the feasibility of our plant production technology for the large-scale manufacture of human insulin. Plants are a transformative platform for the production of biopharmaceuticals. They are ideally suited to large volume products such as human insulin, where capacity is in short supply. Plants offer unprecedented capacity and flexibility for low-cost biopharmaceutical manufacturing and provide by far the most attractive economics, both in
'"/>